作者:翁健
2018-07-04 19:52來源:證券時報
復星醫藥(600196)7月(yue)4日(ri)晚間公告,7月(yue)4日(ri),控股(gu)股(gu)東(dong)復星高(gao)科(ke)技(ji)以均價約39.92港元/股(gu)的(de)價格(ge)增持公司(si)H股(gu)股(gu)份共計50萬(wan)股(gu),增持金額折合約1695萬(wan)元。增持后,復星高(gao)科(ke)技(ji)持有公司(si)38.04%股(gu)權(quan)。
中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)聲明:凡本網(wang)(wang)(wang)注明“來源:中(zhong)(zhong)(zhong)國證(zheng)(zheng)券(quan)報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)”的所(suo)有作(zuo)(zuo)品,版(ban)權(quan)均屬于(yu)中(zhong)(zhong)(zhong)國證(zheng)(zheng)券(quan)報、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)。中(zhong)(zhong)(zhong)國證(zheng)(zheng)券(quan)報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)與(yu)作(zuo)(zuo)品作(zuo)(zuo)者(zhe)(zhe)聯(lian)合聲明,任何組織未經(jing)中(zhong)(zhong)(zhong)國證(zheng)(zheng)券(quan)報、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)以及(ji)作(zuo)(zuo)者(zhe)(zhe)書面授權(quan)不(bu)得轉(zhuan)載(zai)、摘編或利用(yong)(yong)其(qi)它方式使用(yong)(yong)上述作(zuo)(zuo)品。凡本網(wang)(wang)(wang)注明來源非中(zhong)(zhong)(zhong)國證(zheng)(zheng)券(quan)報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)的作(zuo)(zuo)品,均轉(zhuan)載(zai)自其(qi)它媒(mei)體,轉(zhuan)載(zai)目的在于(yu)更好(hao)服務(wu)讀(du)者(zhe)(zhe)、傳遞信息之需,并不(bu)代表本網(wang)(wang)(wang)贊同其(qi)觀點,本網(wang)(wang)(wang)亦不(bu)對(dui)其(qi)真實性負(fu)責,持異(yi)議者(zhe)(zhe)應與(yu)原出(chu)處單位主張權(quan)利。
2016年度“金牛理財產品”頒獎典...
第二十一屆(2017年度)中國資本...
中水集團遠洋股份有限公司投資者...
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明 關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1 Copyright 2001-2018 China Securities Journal. All Rights Reserved
中國證券報社版權所有,未經書面授(shou)權不得復(fu)制(zhi)或建(jian)立鏡像(xiang)
經營(ying)許可證編號:京B2-20180749 京公網安(an)備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved